Publications by authors named "Mirjam de With"

Claim this Profile
D
Dose-individualisation of fluoropyrimidines based on pre-treatment serum uracil levels: the Alpe2U study.
Jonathan E Knikman, Mirjam de With, Niels Heersche, Marta Lopez-Yurda, Arnold Baars

Eur J Cancer· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Irinotecan-Induced Toxicity: A Pharmacogenetic Study Beyond UGT1A1.
Mirjam de With, Leni van Doorn, Esmay Kloet, Anne van Veggel, Maja Matic

Clin Pharmacokinet· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response to "Plasma Uracil as a DPD Phenotyping Test: Pre-analytical Handling Matters".
Mirjam de With, Jonathan Knikman, Jan H M Schellens, Hans Gelderblom, Annemieke Cats

Clin Pharmacol Ther· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Capecitabine-induced hand-foot syndrome: A pharmacogenetic study beyond DPYD.
Mirjam de With, Leni van Doorn, Demi C Maasland, Tessa A M Mulder, Esther Oomen-de Hoop

Biomed Pharmacother· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response to letter entitled re: UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients: Is it time for everyone treated with irinotecan to be tested for UGT1A1 gene polymorphism?
Emma C Hulshof, Mirjam de With, Geert-Jan Creemers, Henk-Jan Guchelaar, Ron Hj Mathijssen

Eur J Cancer· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dihydropyrimidine Dehydrogenase Phenotyping Using Pretreatment Uracil: A Note of Caution Based on a Large Prospective Clinical Study.
Mirjam de With, Jonathan Knikman, Femke M de Man, Carin A T C Lunenburg, Linda M Henricks

Clin Pharmacol Ther· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
as a Predictor of Severe Fluoropyrimidine-Related Adverse Events.
Mirjam de With, Gemma Brufau, Laila A van den Berg, Femke M de Man, Marija Trajkovic

JCO Precis Oncol· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical implications of germline variations for treatment outcome and drug resistance for small molecule kinase inhibitors in patients with non-small cell lung cancer.
Niels Heersche, G D Marijn Veerman, Mirjam de With, Sander Bins, Yehuda G Assaraf

Drug Resist Updat· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients.
Emma C Hulshof, Mirjam de With, Femke M de Man, Geert-Jan Creemers, Birgit A L M Deiman

Eur J Cancer· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Genotyping in Clinical Practice: Ready for Implementation?
Tessa A M Mulder, Ruben A G van Eerden, Mirjam de With, Laure Elens, Dennis A Hesselink

Front Genet· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Germline Variation in Is Associated with Overall Survival in Patients with Metastatic Melanoma Treated with Anti-PD-1 Monotherapy.
Mirjam de With, Daan P Hurkmans, Esther Oomen-de Hoop, Ayoub Lalouti, Sander Bins

Cancers (Basel)· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Genotyping to Personalize Adjuvant Tamoxifen Treatment in ER-Positive Breast Cancer Patients: Current Status of a Controversy.
Tessa A M Mulder, Mirjam de With, Marzia Del Re, Romano Danesi, Ron H J Mathijssen

Cancers (Basel)· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The influence of single-nucleotide polymorphisms on overall survival and toxicity in cabazitaxel-treated patients with metastatic castration-resistant prostate cancer.
Bodine P S Belderbos, Mirjam de With, Rajbir K Singh, Bram C Agema, Samira El Bouazzaoui

Cancer Chemother Pharmacol· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Influence of Genetic Variation in on Cisplatin-Induced Nephrotoxicity in Cancer Patients.
Bram C Agema, Stijn L W Koolen, Mirjam de With, Nadia van Doorn, Niels Heersche

Genes (Basel)· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of pharmacogenetic variants on vemurafenib-related toxicities in patients with melanoma.
Andrew Kl Goey, Mirjam de With, Bram C Agema, Esther Oomen-De Hoop, Rajbir K Singh

Pharmacogenomics· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Influence of the Proton Pump Inhibitor Esomeprazole on the Bioavailability of Regorafenib: A Randomized Crossover Pharmacokinetic Study.
Femke M de Man, Koen G A M Hussaarts, Mirjam de With, Esther Oomen-de Hoop, Peter de Bruijn

Clin Pharmacol Ther· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis